Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial
Nature Medicine, Published online: 16 September 2026; doi:10.1038/s41591-026-04636-8 In this single-arm phase 1 trial, an AAV gene therapy carrying the Padua variant of factor IX was well tolerated in 11 adolescents with hemophilia B and led to…
Read the full story at Nature Medicine ↗
ImpactNotable 38/100
Why it mattersRule-based estimate: no strong signals; trust 10/10.
RegionsGlobal
Published3 d ago (Wed, 16 Sep 2026 00:00:00 GMT)
RetrievedWed, 16 Sep 2026 10:30:17 GMT via rdf
ClassifiedWed, 16 Sep 2026 10:30:34 GMT by heuristic
AuthorFeng Xue